Use of capsule endoscopy to identify lesions suggestive of Crohn's disease in patients with moderate to severe psoriasis - 14/09/17
Doi : 10.1016/j.jaad.2017.02.051
Robert Bissonnette, MD, MSc, FRCPC a, ⁎ 
, Raja Tamaz, MD b, Chantal Bolduc, MD a, Catherine Maari, MD a, Caroline Robillard, DESS, PMP a, Simon Nigen, MD a, Isabelle Delorme, MD c, Charles Lynde, MD d
, Raja Tamaz, MD b, Chantal Bolduc, MD a, Catherine Maari, MD a, Caroline Robillard, DESS, PMP a, Simon Nigen, MD a, Isabelle Delorme, MD c, Charles Lynde, MD d a Innovaderm Research, Hôpital du Sacre-Coeur de Montréal, Montréal, Ontario, Canada
b Department of Gastroenterology, Hôpital du Sacre-Coeur de Montréal, Montréal, Ontario, Canada
c private Practice, Drummondville, Quebec, Ontario, Canada
d Lynderm Research Inc, Markham, Ontario, Canada
∗Correspondence to: Robert Bissonnette, MD, MSc, FRCPC, Innovaderm Research, 1851 Sherbrooke E, Ste 502, Montreal, Quebec H2K 4L5, Canada.Innovaderm Research1851 Sherbrooke ESte 502MontrealQuebecH2K 4L5Canada
| Supported by an Investigator Grant from Abbott/AbbVie. Abbott/AbbVie approved the design of the study and provided funding. |
|
| Dr Bissonnette has received grants and research support, served as a consultant or received honoria from AbbVie, Amgen, Apopharma, Boehringer Ingelheim, Celgene, Dermira, Eli Lilly, Galderma, GSK-Stiefel, Merck, Incyte, Janssen, Kineta, Leo Pharma, Merck, Novartis, Pfizer, Tribute, and Xenoport. Dr Bolduc has served as a consultant or received Honoria from AbbVie, Amgen, Celgene, Eli Lilly, Galderma, GSK-Stiefel, Janssen, Leo Pharma, Merck, Novartis, Tribute, Pfizer, Incyte, and Xenoport. Dr Maari has received grants and research support or received Honoria from AbbVie, Amgen, Apopharma, Boehringer Ingelheim, Celgene, Dermira, Eli Lilly, Galderma, Merck, Incyte, Janssen, Kineta, Leo Pharma, Novartis, Valeant, Pfizer, and Tribute. Dr Nigen has served as a consultant or received Honoria from AbbVie, Amgen, Celgene, Eli Lilly, Galderma, Janssen, Leo Pharma, Merck, Novartis, and Tribute. Dr Delorme served as speaker, advisory board or principal investigator and received Honoria from AbbVie, Actellion, Amgen, Celgene, Dermira, Dignity Science, Eli Lilly, Innovaderm Research, Galderma, Janssen, Kineta, Leo Pharma, Novartis, Regeneron, Vitae, Moberg Pharma, and Cutanea. Dr Lynde served as consultant, speaker, advisory board and principal investigator and received Honoria from AbbVie, Amgen, Boehringer Ingelheim, Celgene, Dermira, and Eli Lilly. Dr Tamaz and Ms Robillard have no conflicts of interest to declare. |
|
| Approved by a research ethics board (IRB services, Aurora, Ontario, Canada) on February 23, 2012. Registered on ClinicalTrials.Gov on March 15, 2012 before the first subject enrollment (NCT01556672). |
© 2017
American Academy of Dermatology, Inc.. Publié par Elsevier Masson SAS. Tous droits réservés.
Vol 77 - N° 4
P. 755-756 - octobre 2017 Retour au numéro
Article précédent
- A phase 2a, open-label pilot study of the galectin-3 inhibitor GR-MD-02 for the treatment of moderate-to-severe plaque psoriasis
- Simon Ritchie, Danielle Neal, Harold Shlevin, Adam Allgood, Peter Traber
- A cross-sectional study of psoriasis triggers among different ethno-racial groups
- Di Yan, Ladan Afifi, Caleb Jeon, Kelly M. Cordoro, Wilson Liao
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?